Physician profile
Poonam Ramsdell
NPI 1467918250
$2,001.38
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.97 · 2022: $417 · 2023: $1,404 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $622.87 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $227.21 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $160.87 | 2023 | Entyvio, Gattex |
| Ardelyx, INC. | $156.11 | 2023 | Ibsrela |
| Janssen Biotech, INC. | $155.79 | 2023 | Stelara |
| Celgene Corporation | $125.40 | 2023 | Zeposia |
| Genzyme Corporation | $100.93 | 2022 | |
| Eisai INC. | $84.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.30 | 2023-2024 | Trulance, Xifaxan |
| Pfizer INC. | $72.03 | 2021-2023 | |
| Sandoz INC. | $47.39 | 2023-2024 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $42.36 | 2023-2024 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.12 | 2023 | Cyltezo |
| Gilead Sciences, INC. | $25.99 | 2023 | |
| Ethicon US, LLC | $17.28 | 2024 | Vistaseal |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $15.78 | 2023 | Hadlima |
| Lilly USA, LLC | $15.72 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $15.24 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Ramsdell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.